CXCL12/CXCR4 signaling has been implicated in the development of metastatic disease in PC and anti-chemokine therapies limit the initial establishment of bone metastases in mice models through targeting tumor stromal interactions in bone tumor microenvironment. Here, CXCR4 is linked to pachyonychia congenita.